---
layout: default
title: Cinchocaine
parent: 僅模型預測 (L5)
nav_order: 217
evidence_level: L5
indication_count: 7
---

# Cinchocaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **7** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cinchocaine: From Local Anesthesia to Bronchitis

## One-Sentence Summary

Cinchocaine (DrugBank DB00527) is an amide-type local anesthetic established for topical/mucosal pain relief.
The TxGNN model predicts it may be effective for **Bronchitis**, with a prediction score of **99.77%**,
but currently **no clinical trials and no publications** support this direction — it is a pure model-level hypothesis.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Local anaesthesia (topical/mucosal use) — specific NPRA label indication text not available in source data |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L5 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known pharmacology, Cinchocaine is an amide-class local anesthetic that blocks voltage-dependent sodium channels to inhibit neural conduction, and it also has mild topical mucosal analgesic and membrane-stabilizing (weak anti-inflammatory) effects. Its established clinical use is local/topical pain relief.

Bronchitis, by contrast, is primarily an inflammatory/infectious airway condition. The TxGNN evidence pack's own mechanistic rationale for this candidate explicitly characterizes the link as weak: cinchocaine has no established anti-inflammatory or antimicrobial pathway relevant to bronchitis, and any connection would be limited to non-specific local antitussive/analgesic effects on airway mucosa rather than a mechanism addressing the underlying pathology.

Given the absence of a plausible direct mechanistic pathway and the complete absence of supporting clinical or literature evidence, this candidate should be treated as an early-stage, exploratory model output rather than a pharmacologically well-grounded hypothesis.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Malaysia Market Information

The NPRA record confirms Cinchocaine is marketed in Malaysia with 1 active registration, but the source data does not contain populated license number, product name, dosage form, or approved-indication-text fields for this entry — these details will need to be retrieved directly from the NPRA product registry before further evaluation.

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: Retrieval of the NPRA label — warnings and contraindications — is flagged as a Blocking data gap; this prevents completion of even the S1 preliminary safety assessment for this candidate.)*

## Other Model-Predicted Candidates (Same Drug)

TxGNN also flagged six additional low-confidence indications for Cinchocaine, all at evidence level L5 with no supporting trials or literature, and all recommended Hold:

| Rank | Predicted Indication | Score | Mechanistic Plausibility |
|------|----------------------|-------|---------------------------|
| 2 | Acrodermatitis chronica atrophicans | 99.76% | None — chronic Borrelia infection; cinchocaine has no antimicrobial activity |
| 3 | Neonatal dermatomyositis | 99.72% | None — autoimmune/complement-mediated; no immunomodulatory action |
| 4 | Secondary childhood ILD with connective tissue disease | 99.72% | None — fibrotic/autoimmune lung pathology unrelated to sodium-channel blockade |
| 5 | Acne keloid | 99.67% | Weak — possible symptomatic analgesia only, no antifibrotic/antimicrobial effect |
| 6 | Hydroa vacciniforme, familial | 99.66% | None — EBV-driven photosensitivity/lymphoproliferation |
| 7 | Amyopathic dermatomyositis | 99.65% | None — type I interferon-driven autoimmune pathology |

This pattern (uniformly high TxGNN scores with uniformly weak, non-specific mechanistic justification and zero real-world evidence) suggests these are broad model-level associations rather than drug-specific repurposing signals, and warrants caution before further investment in any single candidate.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Bronchitis prediction rests solely on a TxGNN model score (L5) with no clinical trials, no literature, and an explicitly weak mechanistic rationale. In addition, a Blocking data gap (missing NPRA label warnings/contraindications) prevents even a preliminary safety assessment, and MOA data has not been formally confirmed.

**To proceed, the following is needed:**
- Retrieve the NPRA product label (warnings, contraindications) for the Malaysia-registered Cinchocaine product — resolves DG001 (Blocking)
- Confirm mechanism of action via DrugBank/pharmacology reference — resolves DG002 (High)
- Complete missing Malaysia registration details (license number, product name, dosage form, approved indication text)
- Independent literature/preclinical search specifically for cinchocaine (or class analogs) in airway inflammation, to test the mechanistic hypothesis before committing to trial-stage evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

